Compare EVC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | FDMT |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.9M | 695.3M |
| IPO Year | 2000 | 2019 |
| Metric | EVC | FDMT |
|---|---|---|
| Price | $7.39 | $13.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $27.82 |
| AVG Volume (30 Days) | ★ 935.3K | 773.8K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 47.59 | 18.79 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $536,034,000.00 | $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $56.84 |
| P/E Ratio | $23.20 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $1.95 | $6.96 |
| 52 Week High | $13.74 | $16.93 |
| Indicator | EVC | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 50.33 |
| Support Level | $2.89 | $13.39 |
| Resistance Level | $10.09 | $15.29 |
| Average True Range (ATR) | 0.29 | 0.88 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 7.01 | 37.21 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).